Resilience Texas, LLC

Resilience Texas LLC operates CTMC, a joint venture of Resilience and MD Anderson Cancer Center, established to accelerate development and manufacturing of innovative cell therapies for cancer patients. It supports biotech partners with process and analytical development, GMP manufacturing, logistics, and regulatory assistance, combining manufacturing capabilities with MD Anderson’s clinical-trial expertise. Its patient-adjacent Houston facility helps advance therapies from early development toward clinical testing and commercial readiness.